Sciencast Management LP Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Sciencast Management LP lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,994 shares of the medical equipment provider’s stock after selling 4,854 shares during the quarter. Sciencast Management LP’s holdings in Hologic were worth $1,325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic in the 4th quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV grew its stake in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the period. Allworth Financial LP grew its stake in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares during the period. Mather Group LLC. purchased a new stake in shares of Hologic in the first quarter worth $48,000. Finally, Toth Financial Advisory Corp grew its stake in shares of Hologic by 81.1% in the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.6 %

Shares of Hologic stock traded up $1.20 on Friday, reaching $77.69. The company had a trading volume of 1,694,534 shares, compared to its average volume of 1,619,938. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The firm has a market cap of $18.13 billion, a price-to-earnings ratio of 39.64, a P/E/G ratio of 2.52 and a beta of 0.99. The firm’s 50-day moving average price is $74.02 and its two-hundred day moving average price is $74.54.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company earned $1.06 EPS. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. As a group, research analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HOLX. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Argus raised their price objective on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Evercore ISI cut their target price on Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a research report on Tuesday, July 2nd. Finally, Stephens initiated coverage on Hologic in a research report on Thursday, June 27th. They set an “overweight” rating and a $87.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.